Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorUniversity of Virginia
About this trial
The purpose of this study is to assess preliminary efficacy of a tailored cognitive bias modification for interpretation (CBM-I) app for reducing anxiety in Huntington's disease and Parkinson's disease.
Eligibility criteria
Qualifiers
Clinical diagnosis of Huntington's disease or Parkinson's disease (genetic diagnosis of HD also acceptable)
With anxiety symptoms (NeuroQoL Anxiety ≥12)
Disqualifiers
Cognitive decline precluding ability to consent or complete the intervention (MoCA 5 min/telephone ≤11)
Unable to read and understand English
Does not have regular access to an internet-connected device, capable of downloading and installing the mobile application (i.e., tablet or iPhone running iOS 10 or later or an Android phone running Android 5.0 or later)
Not located in the USA
Trial design
Treatments tested in this trial
- MindTrails-Movement
- Waitlist Control
Treatment groups
136 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Virginia
Lead sponsor
National Institute of Nursing Research (NINR)
Collaborator
Source ClinicalTrials.gov